CORRECTED January 18, 2024 // Editor's note: An earlier version of this story erroneously stated that Medicare has started covering use of the AI-based cancer test. Neither the company nor CMS provided Medscape with information on how much the payment will be should the agency agree to cover the test.
Medicare has set a payment rate for an AI-based test for prostate cancer that can predict which men will benefit from potentially disabling androgen deprivation therapy.
The Centers for Medicare & Medicare Services (CMS) on January 1 approved the payment rate for ArteraAI as a clinical diagnostic laboratory test. The test is the first that can both predict therapeutic benefit and prognosticate long-term outcomes in localized prostate cancer.
Daniel Spratt, MD, chair of radiation oncology at UH Seidman Cancer Center in Cleveland, who has been involved in researching ArteraAI, told Medscape Medical News, said the test improves risk stratification or prognostication over standard clinical and pathologic tools, such as prostate-specific antigen, Gleason score, and T-stage, or risk groupings such as those from the National Comprehensive Cancer Network (NCCN).
"Medicare approval allows this test to reach more patients without the financial burden of covering the test out of pocket. The test is found among other tests in NCCN guidelines as a tool to improve risk stratification and personalization of treatment," said Spratt, who serves on the network's prostate cancer panel.
ArteraAI combines a patient's standard clinical and pathologic information into an algorithm, alongside a digitized image analysis of the patients' prostate biopsy. The result is a score that estimates a patient's risk of developing metastasis or dying from prostate cancer.
Spratt was the lead author of article last June in NEJM Evidence that validated ArteraAI. He said ArteraAI is 80% accurate as a prognostic test compared with 65% accuracy using NCCN stratification systems.
The AI test spares about two thirds of men with intermediate-risk prostate cancer who are starting radiation therapy from androgen deprivation and its side effects, such as weight gain, breast enlargement, hot flashes, heart disease, and brain problems, Spratt added.
Andre Esteva, CEO and co-founder of San Francisco-based ArteraAI, said, "After someone is diagnosed with localized prostate cancer, deciding on a treatment can feel very overwhelming as there are so many factors to consider. During this time, knowledge is power, and having detailed, personalized information can increase confidence when making these challenging decisions. The ArteraAI Prostate Test was developed with this in mind and can predict whether a patient will benefit from hormone therapy and estimate long-term outcomes."
Bruno Barrey is one of Spratt's patients. Barrey, a robotics engineer from suburban Detroit who was transitioning from active surveillance with Gleason 3+4 intermediate-risk prostate cancer to radiation therapy, said, "I was concerned about the side effects from androgen-deprivation therapy. I was relieved that the AI test allowed me to avoid hormone therapy."
Spratt reported working with NRG Oncology, a clinical trials group funded by the National Cancer Institute, and as an academic collaborator with ArteraAI.Â
Howard Wolinsky is a Chicago-based medical freelance writer. He just observed his 13th year on active surveillance for low-risk prostate cancer, what he calls his "pros mitzvah." He is working on a Master of Public Health at the University of Illinois Chicago School of Public Health.
Â